Editas Medicine (EDIT) Stock Price, News & Analysis

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares.
View EDIT analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 1 year price targets for Editas Medicine's stock. Their EDIT share price targets range from $9.00 to $20.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 150.8% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.

Editas Medicine's stock was trading at $10.13 at the start of the year. Since then, EDIT shares have decreased by 41.0% and is now trading at $5.98.
View the best growth stocks for 2024 here.

Editas Medicine saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 16,360,000 shares, an increase of 17.4% from the March 15th total of 13,930,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the days-to-cover ratio is currently 8.9 days.
View Editas Medicine's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our EDIT earnings forecast.

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.29. The business earned $60 million during the quarter, compared to the consensus estimate of $4.84 million. Editas Medicine had a negative trailing twelve-month return on equity of 42.95% and a negative net margin of 196.12%. Editas Medicine's revenue for the quarter was up 817.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.88) earnings per share.

ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Direxion Moonshot Innovators ETF (MOON), Horizon Kinetics Medical ETF (MEDX) and AXS Green Alpha ETF (NXTE).WisdomTree BioRevolution Fund (WDNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

Editas Medicine (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.